Medical/Pharmaceuticals

Kintor Pharma's Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study

* Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p <0.02). * Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors. * Proxalutamid...

2022-04-06 09:22 1555

Singlera Genomics announces research collaboration with Astellas Pharma pursuing methylation-based tools to better understand biological reactions to pharmaceuticals

SAN DIEGO and TOKYO, April 5, 2022 /PRNewswire/ -- Singlera Genomics Inc. today announced a research collaboration with Astellas Pharma Inc. to develop methylation-based tools to better understand biological reactions to pharmaceuticals using Singlera's mTitan platform. mTitan allows for the int...

2022-04-05 21:56 1714

Nihon Medi-Physics Attains World's First Manufacturing of Actinium-225 with Cyclotron on Production Scale for Investigational Drugs

- Core Material Used for Targeted Alpha Therapy (TAT) Expected to Be Novel Treatment for Cancer - TOKYO, April 5, 2022 /PRNewswire/ -- Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company inJapan, announced on April 5, 2022, that the company has successfully manufactured act...

2022-04-05 16:00 2126

Formus Labs Adds Seasoned Medical Technology Executives Lloyd McCann and Meraj Khan to Board of Directors

Formus combines AI and biomechanics in fully automated preoperative planning workflows that empower orthopedic surgeons to optimize patient outcomes AUCKLAND, New Zealand, April 5, 2022 /PRNewswire/ --  Formus Labs, creator of the world's first fully-automated 3D planner for joint replacement sur...

2022-04-05 03:00 2086

Indonesia's Ministry of Health Discussed a Universal Vaccine Passport and Verifier for International Travelers

JAKARTA, April 4, 2022 /PRNewswire/ -- Assuming the presidency in the upcoming G20 summit,Indonesia has begun the Health Working Group (HWG) meeting series that took place on28-30 March 2022 in Yogyakarta, Indonesia. Indonesia's Ministry of H...

2022-04-04 23:35 2008

Vieworks to Make Its Debut at AACR Annual Meeting 2022 with VISQUE InVivo Series

ANYANG, South Korea, April 4, 2022 /PRNewswire/ -- Vieworks will be showcasing its optical in vivo imaging systems at AACR Annual Meeting (April 10-13, booth 2308). VISQUE InVivo Art is Vieworks' premium preclinical optical imaging system for high-sensitivity fluorescent & bioluminescent imaging ...

2022-04-04 21:00 2047

Dada's JDDJ in action to guarantee medical supply and online health consultation with pharmaceutical partners

SHANGHAI, April 2, 2022 /PRNewswire/ -- As a number of cities in China are ramping up anti-epidemic measures, more consumers rely on online-to-offline services to purchase much-needed medications. JDDJ, one ofChina's largest local on-demand retail platforms operated by Dada Group (Nasdaq: DADA), ...

2022-04-02 20:53 3331

REDUCE LAP-HF II ANALYSES SHOW 50% OF STUDY PATIENTS DEMONSTRATED SIGNIFICANT CLINICAL BENEFIT FROM THE CORVIA® ATRIAL SHUNT

  Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, Mass., April 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, ...

2022-04-01 18:03 2242

Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers

SHANGHAI, April 1, 2022 /PRNewswire/ -- Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced today the successful completion of the fi...

2022-04-01 16:55 1607

Akeso Reported 2021 Annual Results

Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology,...

2022-04-01 13:44 24769

Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06

SHANGHAI, March 31, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first particip...

2022-03-31 23:40 1346

Aceemzyme Co., Ltd., challenging to new drug of brain diseases with recombinase-based ginsenoside Rh2 (s) mass production technology…

- Under development of ginsenoside Rh2(s) mass production technology… - "Enhanced production of ginsenoside Rh2(S) from PPD-type major ginsenosides using BglSk cloned fromSaccharibacillus kuerlensis together with two glycosidase in series" SOUTH KOREA, Seoul, March 31, 2022 /PRNewswire/ -- Ginse...

2022-03-31 21:00 985

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Grou...

2022-03-31 20:00 1297

China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results

HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the fiscal...

2022-03-31 20:00 3702

CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda

* CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs * Hasten fast-tracks transformative medicines for patients in China SHANGHAI, March 31, 2022 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired a ...

2022-03-31 15:05 1707

LifeTech Scientific Corporation(1302.HK) Announces 2021 Annual Results

Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by  76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...

2022-03-31 03:27 3019

Keymed Biosciences Releases 2021 Annual Results

CHENGDU, China, March 30, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX Code: 02162) released 2021 annual results. BUSINESS HIGHLIGHTS  On July 8, 2021, Keymed was listed on the HKEX. During the Reporting Period, the Company continued proceeding the R&D of products and made the following p...

2022-03-30 23:41 2374

First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights

SUZHOU, China, March 29, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...

2022-03-30 10:35 1907

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned up...

2022-03-29 23:00 1831

MedTech Baymatob completes capital raise to advance life-saving labor monitoring device

SYDNEY, March 29, 2022 /PRNewswire/ -- Medical device company Baymatob has completed a placement ofA$4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labor monitoring device, Oli. Cornerstoned by Australian Unity's Future of Healthcare Fund, the placement ...

2022-03-29 21:34 1707
1 ... 132133134135136137138 ... 215